Management are keeping their focus & giving the market a clear vision of a eastern Canada launch in the not to distant future.

 

So who want's a piece of the pie ?

 

Miraculins Inc.
 

December 20, 2012 07:00 ET

Miraculins Announces Expansion of PreVu® Testing to All London Drugs Pharmacies

 

Successful Vancouver/Winnipeg Pilots Lead to Storewide Rollout

 

 

WINNIPEG, MANITOBA--(Marketwire - Dec. 20, 2012) - Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs; London Drugs, one of Canada's leading pharmacy chains; and Pear Healthcare Solutions, a leading provider of in-pharmacy health screening and educational services, today announce that London Drugs will be expanding its offering of the PreVu® Non-Invasive Skin Cholesterol Point of Care (POC) Test to all 76 physical pharmacy locations in more than 35 major markets throughout Western Canada.

"I am pleased to confirm that we will be expanding our PreVu POC Test programming to all of our stores beginning in March 2013," said John Tse, Vice President, Pharmacy for London Drugs. "Based on a very successful pilot at our pharmacy locations in Vancouver and the Lower Mainland, as well as in Winnipeg, and the positive response of the public and our pharmacy team, we see significant value in bringing the PreVu POC Test to customers throughout our entire network of stores, to help them better understand their potential risk of coronary artery disease."

"The Canadian launch of PreVu through London Drugs has established the viability and potential of distributing this revolutionary new screening technology through a retail pharmacy platform," said Paul Moreau, Vice President, Sales and Marketing for Miraculins Inc. "We have been diligent in advancing the business model for the pharmacy market given its enormous consumer reach, and these pilots have allowed us to further refine and prepare the model for duplication. The pioneering vision of London Drugs, further underscored by its decision to expand PreVu to all of its stores, signals the graduation of a test delivery system that can now be replicated in pharmacies across the country and internationally."

Based upon a patient's PreVu test results, formal risk assessment under a healthcare provider's direction, including blood cholesterol testing and global risk assessment, may be warranted, or should be considered. The PreVu POC Test does not diagnose the presence or absence of coronary artery disease (CAD), but without blood draw or fasting it can quickly identify individuals who may possess hidden, higher levels of risk of CAD by measuring their skin cholesterol levels, and encouraging them to see their doctors. Clinical studies have shown that elevated skin cholesterol is strongly associated with an increased risk of serious atherosclerotic disease.* PreVu is not a substitute for blood serum cholesterol testing.

Miraculins also recently announced the launch of its French language web site for PreVu for the Canadian marketplace (www.prevu.com) and issued a year-end summary report on PreVu operating, marketing and distribution progress.